New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
16:37 EDTWXWuXi PharmaTech narrows FY12 revenue view to $495M-$498M from $488M-$498M
FY12 consensus $496.85M. Sees FY12 operating margin of about 17.5% on a GAAP basis and about 20.5% on a non-GAAP basis, compared to previous guidance of 17%-18.0% and 20.0%-21.0%, respectively.
News For WX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
08:02 EDTWXWuXi PharmaTech's STA subsidiary receives approval from Japanese authorities
WuXi PharmaTech announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. received its first approval from the Japan PMDA for the manufacture of the GMP intermediate of a branded commercial drug in July. STA is now the only Chinese contract manufacturing organization to have received approval to supply active pharmaceutical ingredients and GMP intermediates for branded commercial drugs from regulatory agencies in the United States, Canada, the European Union, Switzerland, China, Japan, Australia, and New Zealand.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use